MedTrace Logo

Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT

NCT06686173 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 114

Last updated 2025-01-07

No results posted yet for this study

Summary

This is a prospective, multicenter, cohort study. The high-risk, relapse and refractory AML patients were enrolled in this study. And the goal of this study is to study the effect of the parous female donor and young male donor on the outcomes of graft-versus-host disease (GVHD) prophylaxis underwent the combination of ATG and PTCy for haploidentical peripheral blood stem cell transplantation

Conditions

  • High-Risk Acute Myeloid Leukemia
  • Relapse And/or Refractory AML

Interventions

OTHER

None-placebo

This is one kind descriptive study. The different donor groups made the cohorts different: the parous female donor and young male donor

OTHER

non-intervention study

This study is one kind of non intervention study

OTHER

donor selection

the intervention of this study was the different donor groups: the parous female donor and young male donor. All the patients involved in this study were treated by the combination of ATG and PTCy

Sponsors & Collaborators

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2027-02-01
Completion
2028-02-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686173 on ClinicalTrials.gov